ArticleEndocrine2017
Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).
Article in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Practice Guidelines for the Diagnosis and Treatment of Subepithelial Lesion Observed in Upper Gastrointestinal Endoscopy.Journal of gastroenterology and hepatology · 2026Guideline
- Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis.World journal of gastroenterology · 2019Pooled it
- Neuroendocrine neoplasms of the stomach. Update on diagnostic criteria, classification, and prognostic markers.Virchows Archiv : an international journal of pathology · 2026Review
- Practice Guidelines for the Diagnosis and Treatment of Subepithelial Lesions Observed in Upper Gastrointestinal Endoscopy.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Last decade of advances in gastric neuroendocrine tumors: Innovations, challenges, and future directions.World journal of clinical oncology · 2025Article
- The Role of Dopamine in Gastric Cancer-A Systematic Review of the Pathogenesis Phenomena Developments.Biomedicines · 2024Review
- Management of Gastric Neuroendocrine Tumors: A Review.Annals of surgical oncology · 2024Review
- Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment.Frontiers in endocrinology · 2024Review
- Clinical characteristics and long-term prognosis of type 1 gastric neuroendocrine tumors in a large Japanese national cohort.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2023Article
- Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs.Cancers · 2023Review
- Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are.World journal of gastroenterology · 2022Article
- Gastric neuroendocrine tumor: A practical literature review.World journal of gastrointestinal oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGastric neuro-endocrine tumours are rare. European guidelines for the management of neuro-endocrine tumours have been published in 2012. The aim of our survey was to study the management of gastric neuro-endocrine tumours registered in the national cohort. A prospective national cohort registers the Neuro-endocrine tumours in France since January 2003 (GTE network). We reviewed all the individual medical reports of gastric neuro-endocrine tumours in order to collect data on treatment.
resultsOne hundred and ninety seven gastric neuro-endocrine tumours diagnosed between 1964 and 2013 in 20 centres were registered. For 181 cases data were considered complete for our survey. Eighty four tumours were type 1 (46.4%); five types 2 (2.8%); 52 types 3 (28.7%) and 40 types 4 (22.1%). Types 1 and 2 were first endoscopically managed in 93 and 60% of cases, respectively, whereas surgery was first done in 45 and 42%, respectively, of types 3 and 4. Systemic treatment, chemotherapy and/or somatostatin analogue, was first administered exclusively for types 3 and 4. Near 3% of types 1 and 40% of types 2 received at a time somatostatin analogue treatment. Five-year survival rates were 98.3, 100, 63.2 and 31.8% for types 1, 2, 3 and 4, respectively.
conclusionThe great majority of gastric neuro-endocrine tumours registered in this national cohort are treated in accordance with the current guidelines. The survival rates we reported must be interpreted with caution, because this cohort registered preferentially selected patients eligible for treatment. The registration of all the gastric neuro-endocrine tumours, in particular type 1 considered as benign and type 4 not eligible for specific anti-cancer treatment must be encouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.